Chagas disease, a parasitic infection caused by Trypanosoma cruzi, is endemic in much of
Latin America and affects people throughout the world. Currently treatment with the only two
drugs effective against the infection, benznidazole and nifurtimox, has significant
limitations including frequent adverse effects in adult patients. However, timely treatment
is key to achieving global objectives of controlling the disease. The standard treatment has
a long duration (60 days). NuestroBen will test the hypothesis that a shorter treatment
regimen of 14 days will be non-inferior to the standard 60-day treatment while improving the
safety profile.